Pfizer releases INLYTA trial data

Pfizer has released data from its Phase 1b INLYTA clinical trial in which the drug is combined with pembrolizumab, a PD-1 inhibitor called KEYTRUDA, and marketed by Merck.

INLYTA has been designated to treat patients who are suffering from advanced renal cell carcinoma (RCC).

The Phase 1b trial was developed to assess INLYTA’s safety and anti-tumor activity, as well as establish dosing options for the drug when it is combined with pembrolizumab for use as a first-line treatment option for advanced RCC.

“Combining immunotherapy agents with currently approved therapies such as INLYTA may provide a meaningful improvement in outcome for patients with renal cancer,” Dr. Chris Boshoff, head of Pfizer’s Global Product Development and immune-oncology, early development and translational oncology, said. “The results presented today indicate that there is a potential additive or synergistic effect between INLYTA and a checkpoint inhibitor in RCC.”

Early results from the trial indicate that the response rate to the combination of INLYTA and pembrolizumab is strong in the 37 patients taking part in the study, with three patients achieving complete responses while 34 patients had partial responses to the combination therapy.